Avenue Therapeutics, Inc. Quarterly report [Sections 13 or 15(d)]

Note 3 - Licenses Supplier Agreements (Details Textual) - USD ($) $ in Millions			1 Months Ended	4 Months Ended
	Oct. 29, 2018	Feb. 17, 2015	Dec. 31, 2019	Jun. 17, 2015
Contractual Obligation Development Expense			$ 81.5
Contractual Obligation, Commercial Expense			$ 151.0
Revogenex License [Member]
Contractual Obligation, Maximum Future Payments				$ 3.0
Baergic Licenses [Member] \| CCHMC [Member]
Percentage of Equity Fee			5.00%
Polpharma [Member]
Payments to Acquire in Process Research and Development	$ 2.0
Fortress Biotech Inc [Member] \| Iv Tramadol [Member]
Payments to Acquire in Process Research and Development		$ 2.0
Fortress Biotech Inc [Member] \| Iv Tramadol [Member] \| Additional Payment [Member]
Payments to Acquire in Process Research and Development				$ 1.0
Fortress Biotech Inc [Member] \| Iv Tramadol [Member] \| Upfront Payment [Member]
Percentage of Equity Fee			20.00%
Baergic Licenses [Member] \| Upfront Payment [Member] \| CCHMC [Member]
Payments to Acquire in Process Research and Development			$ 0.2
Baergic Licenses [Member] \| Upfront Payment [Member] \| AZERBAIJAN
Payments to Acquire in Process Research and Development			$ 3.0